Document:

Amendment to Severance Agreement

 Exhibit 10.6 
 AMENDMENT TO SEVERANCE AGREEMENT 
 This
Amendment (“Amendment”) to the Severance Agreement dated May 24, 2007 (“Agreement”) between R. Bruce Stewart (“Executive”) and Arrowhead Research Corporation (“Company”), a Delaware corporation located at
201 S. Lake Avenue, Suite 703, Pasadena, CA 91101, is made and entered into as May 12, 2009 (“Effective Date”). 
 WHEREAS, the Company and the Executive seek to amend the Agreement; 
 NOW THEREFORE, in consideration of the mutual
covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, such parties intending to be legally bound, agree as follows: 
 Section 3 of the Agreement shall be discharged and rendered moot in its entirety; and shall be replaced with the following
Section 3: 
 3. Retirement or Termination of Employment  
 The following shall govern Executive’s retirement or termination (except in the case of Section 5 below): Should Executive
voluntarily retire or voluntarily terminate from Arrowhead Research Corporation or its successor for any reason or should Executive be terminated from Arrowhead Research Corporation or its successor for any reason, Executive will be paid a single
lump sum amount equivalent to one (1) month of his highest monthly salary while at Arrowhead Research Corporation. 
 IN WITNESSETH
WHEREOF, each of the parties has duly executed the Amendment effective as of the Effective Date. 
  

					
	 Dated: May 12, 2009
	 		 	ARROWHEAD RESEARCH CORPORATION
			
		 		 	 /s/ Paul C. McDonnel

		 		 	Paul C. McDonnel
		 		 	Chief Financial Officer
			
	 Dated: May 12, 2009
	 		 	EXECUTIVE
			
		 		 	 /s/ R. Bruce Stewart

		 		 	R. Bruce Stewart
		 		 	Executive ChairmanAmendment to Employment Agreement

 Exhibit 10.8 
 AMENDMENT TO EMPLOYMENT AGREEMENT 
 This
Amendment (“Amendment”) to the Employment Agreement dated June 11, 2008 (“Agreement”) between Dr. Christopher Anzalone (“Executive”) and Arrowhead Research Corporation (“Company”), a Delaware
corporation located at 201 S. Lake Avenue, Suite 703, Pasadena, CA 91101, is made and entered into as May 12, 2009 (“Effective Date”). 
 WHEREAS, the Company and the Executive seek to amend the Agreement; 
 NOW
THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, such parties intending to be legally bound, agree as
follows: 
 Section 5(b) of the Agreement shall be discharged and rendered moot in its entirety; and replaced with the
following replacement Section 5(b): 
 (b) Termination of Employment. If the Employment Period is
terminated by the Company without Cause or by Executive with Good Reason, Executive shall be entitled to receive (i) a one-time lump sum payment of an amount equal to one month’s Base Salary payable as a special severance payment on the
date of termination; and (ii) a one time lump sum payment of an amount equal to the premiums for thirty (30) days’ of medical and dental benefits on the date of termination. Notwithstanding anything herein to the contrary, no amounts
shall be payable pursuant to this Section 5(b) unless and until Executive has executed and delivered to the Company a general release in favor of the Company in form and substance reasonably satisfactory to the Board and only so long as
Executive has not breached the provisions of Sections 7, 8 and 9 hereof. Except as provided in this Section 5(b), Executive shall not be entitled to any other salary, compensation or benefits after termination of the Employment Period.

 IN WITNESSETH WHEREOF, each of the parties has duly executed the Amendment effective as of the Effective Date. 
  

					
	 Dated: May 12, 2009
	 		 	ARROWHEAD RESEARCH CORPORATION
			
		 		 	 /s/ Paul C. McDonnel

		 		 	Paul C. McDonnel
		 		 	Chief Financial Officer
			
	 Dated: May 12, 2009
	 		 	EXECUTIVE
			
		 		 	 /s/ Christopher Anzalone

		 		 	Dr. Christopher Anzalone
		 		 	Chief Executive OfficerForm of Subscription Agreement, dated as of September 30, 2009

 Exhibit 10.22 
 SUBSCRIPTION AGREEMENT 
 THIS SUBSCRIPTION
AGREEMENT (this “Agreement”) is made as of the last date indicated on the signature pages hereto between Unidym, Inc., a Delaware corporation (the “Company”), and the undersigned investors parties
hereto (each an “Investor” and collectively, the “Investors”). 
 RECITALS

 WHEREAS, the Company wishes to sell up to an aggregate of
             shares of the Company’s Series D Preferred Stock (“Shares”) to the Investors, at a purchase price of $0.30 per Share, and the
Investors wish to purchase Shares from the Company. 
 NOW, THEREFORE, in consideration of the mutual covenants, agreements and
conditions, and upon acknowledgement of each of the parties of the receipt of valuable consideration, the parties herein agree as follows: 
 1. Purchase and Sale of Shares and Warrants. At the Closing (as defined below), the Company shall issue and sell to each Investor (i) such number of Shares as is set forth immediately below
such Investor’s name on the signature pages hereto, and (ii) a warrant, in the form attached hereto as Exhibit E (the “Warrant”), to purchase such number of shares of Common Stock of the Company
as is set forth immediately below such Investor’s name on the signature pages hereto, against delivery to the Company by such Investor of an amount equal to $0.30 times the number of Shares to be purchased by such Investor (the
“Purchase Price”), paid by (a) cash (by check or wire transfer) in United States Dollars to the Company or (b) cancellation of indebtedness of the Company to such Investor. Promptly after the Closing,
the Company shall deliver to each Investor a duly executed certificate representing the Shares which such Investor is purchasing hereunder. The purchase and sale transaction contemplated hereby will close on the first business day immediately
following the satisfaction of the closing conditions set forth herein, which is targeted to be no later than 5:00 p.m., Pacific Time on September 30, 2009, as such date and time may be modified by the Company in its sole discretion (such day,
the “Closing”). 
 2. Representations and Warranties of the Company. The Company hereby represents and
warrants to Investor, that the statements in the following paragraphs of this Section 2 are all true and complete as of the date hereof: 
 2.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company is duly
qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on (a) the present or future business, assets, or operations, of the
Company, taken as a whole or (b) the Company’s ability to perform this Agreement or its obligations under the Warrant, the Investors’ Rights Agreement, the ROFR Agreement or the Voting Agreement, each as defined below, (collectively,
the “Related Agreements”) (a “Material Adverse Effect”). 
 2.2
Capitalization and Voting Rights. 
 (a) Authorized Stock. There are authorized for issuance (i) 80,000,000
shares of Common Stock, $0.0001 par value per share (“Common Stock”), and (ii) 49,673,250 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”), of which 5,000,000 shares are
designated as Series A Convertible Preferred Stock (“Series A Preferred Stock”), 5,673,252 shares are designated as Series B Senior Convertible Preferred Stock (“Series B Preferred Stock”), 8,500,000
shares are designated as Series C Senior Convertible Preferred Stock (“Series C Preferred Stock”), and 30,499,998 shares are designated as Series D Preferred Stock (“Series D Preferred Stock”).
Immediately prior to the Closing, the outstanding stock of the Company consists of the following: 
 (i) Three
Million Seven Hundred Fifty Five Thousand (3,780,100) shares of issued and outstanding Common Stock. 
  

 1 

 (ii) Five Million (5,000,000) shares of issued and outstanding Series
A Preferred Stock, which shares of Series A Preferred Stock are convertible into 1.680096462 shares of Common Stock upon (x) an involuntary or voluntary liquidation, dissolution and winding up of the Company, (y) a Deemed Liquidation Event
(as such term is defined in the Restated Certificate (as defined below)) or (z) a Qualified IPO (as such term is defined in the Restated Certificate). 
 (iii) Five Million Six Hundred Seventy Three Thousand Two Hundred and Fifty Two (5,673,252) shares of issued and
outstanding Series B Preferred Stock, which shares of Series B Preferred Stock are convertible into 1.000042304 shares of Common Stock. 
 (iv) Eight Million One Hundred Twenty Five Thousand Eight Hundred Eighty-Nine (8,125,889) shares of issued and outstanding Series C Preferred Stock. 
 (v) 15,583,398 shares of issued and outstanding Series D Preferred Stock, all of which shares were issued upon the
conversion of 2,597,233 shares of Series C-1 Preferred Stock, none of which remains outstanding or authorized for issuance. 
 Upon the Closing,
the rights, preferences and privileges of each series of Preferred Stock will be as stated in the Restated Certificate and as provided by law. 
 (b) Valid Issuance. The outstanding shares of Common Stock and Preferred Stock are all duly and validly authorized and issued, fully paid and nonassessable. 
 (c) Rights to Acquire. Except for (i) the conversion privileges of the Preferred Stock, (ii) the rights of first refusal
provided in Section 4 of the Investors’ Rights Agreement, (iii) the Five Million (5,000,000) shares of Common Stock reserved for issuance to employees, consultants and/or directors pursuant to the Company’s 2006 Stock
Option/Stock Issuance Plan (the “Option Plan”), of which options to purchase an aggregate of 2,226,250 shares of Common Stock are currently outstanding, (iv) outstanding warrants to purchase Three Million Six Hundred
Seventy Four Thousand Two Hundred and Eight (3,674,208) shares of Common Stock and (vi) outstanding restricted stock units for the issuance of One Million One Hundred and Four Thousand and Ten (1,104,010) shares of Common Stock, there
are not outstanding any options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or acquisition from the Company of any shares of its capital stock. 
 (d) Voting of Shares. Other than the Voting Agreement, the Company is not a party or subject to any agreement or understanding and,
to the Company’s knowledge, there is no agreement or understanding between any persons and/or entities which affects or relates to the voting or giving of written consents with respect to any security or by a director of the Company.

 (e) Market Stand-Off. To the Company’s best knowledge, all outstanding shares of Preferred Stock of the Company
and all capital stock of the Company issuable upon the exercise of outstanding employee incentive stock options are subject to a one hundred eighty (180) day “market stand-off” restriction upon an initial public offering by the
Company resulting in at least $20 Million in gross proceeds pursuant to a registration statement filed with the Securities and Exchange Commission (“SEC”) pursuant to the Securities Act of 1933, as amended (the
“Act”). 
  

 2 

 2.3 Subsidiaries. Except for (i) the minority ownership position in Nexeon
MedSystems pursuant to the license agreement with Nanotech Catheter Solutions, and (ii) the 100% ownership position in Nanoconduction, Inc., the Company does not presently own or control, directly or indirectly, any interest in any other
corporation, association, or other business entity. The Company is not a participant in any joint venture, partnership, or similar arrangement. 
 2.4 Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement, the Related
Agreements, the performance of all obligations of the Company hereunder and thereunder, and the authorization, sale and issuance of the Shares being sold hereunder, and the Common Stock issuable upon conversion of the Shares, has been taken or will
be taken prior to the Closing. As of the Closing, this Agreement and the Related Agreements constitute valid and legally binding obligations of the Company, enforceable in accordance with their respective terms, except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies, and (iii) to the extent the indemnification provisions contained in the Related Agreements may be limited by applicable federal or state securities laws. 
 2.5 Valid Issuance of Preferred and Common Stock. The Shares that are being purchased by Investor hereunder, when issued, sold and
delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer, other than restrictions on transfer, if any,
(i) under this Agreement, the Investor’s Rights Agreement and the ROFR Agreement, (ii) under applicable state and federal securities laws and (iii) otherwise imposed as a result of actions taken by Investor. The Common Stock
issuable upon conversion of the Shares purchased under this Agreement has been duly and validly reserved for issuance and, upon issuance in accordance with the terms of the Company’s Third Amended and Restated Certificate of Incorporation in
the form attached hereto as Exhibit D (the “Restated Certificate”), will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer, other than restrictions on transfer, if
any (i) under this Agreement, the Investor’s Rights Agreement and the ROFR Agreement, (ii) under applicable state and federal securities laws and (iii) otherwise imposed as a result of actions taken by Investor. 
 2.6 Governmental Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration
or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement and the Related Agreements, except for such consents,
approvals, orders, authorizations, registrations, qualifications, designations, declarations or filings which are not required to be obtained prior to the Closing, and such filings as are required pursuant to applicable federal and state securities
laws and blue sky laws, which filings will be effected within the required statutory period. 
 2.7 Offering. Subject in
part to the truth and accuracy of Investor’s representations set forth in Section 3 of this Agreement, the offer, sale and issuance of the Shares as contemplated by this Agreement are exempt from the registration requirements of the Act,
and the qualification or registration requirements of applicable state blue sky laws, as such registration requirements and laws currently exist. 
 2.8 Litigation. There is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened in writing against the Company that questions the validity of
this Agreement or the Related Agreements, or the right of the Company to enter into such agreements or

  

 3 

 
to consummate the transactions contemplated hereby and thereby, or that would reasonably be expected to result in a Material Adverse Effect. The Company is not a party or subject to the
provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. 
 2.9
Proprietary Information Agreements. Each current employee of the Company has executed a Proprietary Information and Inventions Agreement in substantially the form provided to the Investors upon request by the Investors. The Company is not
aware that any such employee is in violation thereof. 
 2.10 Compliance with Other Instruments. The Company is not in
violation of any provision of its Restated Certificate or Bylaws nor, to its knowledge, of any instrument, judgment, order, writ, decree or contract, statute, rule or regulation to which the Company is subject and a violation of which would
reasonably be expected to have a Material Adverse Effect. The execution, delivery and performance of this Agreement and the Related Agreements, and the consummation of the transactions contemplated hereby and thereby will not result in any such
violation, or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision or an event that results in the creation of any lien, charge or encumbrance upon any assets of the
Company or the suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations or any of its assets or properties. 
 2.11 Agreements; Action. Except for agreements explicitly contemplated hereby, there are no agreements or understandings between the
Company and any of its officers, directors, affiliates or any affiliate thereof (except for quarterly allocations for services performed by Arrowhead (as defined below)), 
 (a) there are no agreements, understandings, instruments, contracts, judgments, orders, writs or decrees to which the Company is a party or
by which it is bound that may involve (i) obligations (contingent or otherwise) of, or payments to the Company, in excess of $10,000, other than obligations of, or payments to, the Company arising from purchase or sale agreements entered into
in the ordinary course of business, or (ii) provisions materially restricting the development, manufacture or distribution of the Company’s products or services, and 
 (b) The Company has not (i) declared or paid any dividends or authorized or made any distribution upon or with respect to any class or
series of its capital stock, (ii) made any loans or advances to any person, other than ordinary advances for travel expenses, or (iii) sold, exchanged or otherwise disposed of any of its assets or rights. 
 For the purposes of subsections (a) and (b) above, all indebtedness, liabilities, agreements, understandings, instruments and contracts involving
the same person or entity (including persons or entities the Company has reason to believe are affiliated therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections. 
 2.12 Related-Party Transactions. No employee, officer or director of the Company or member of his or her immediate family is
indebted to the Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them. To the best of the Company’s knowledge, other than in Arrowhead Research Corporation, a Delaware corporation
(“Arrowhead”) or in any of Arrowhead’s subsidiaries, none of such persons has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a
business relationship, or any firm or corporation that competes with the Company, except that employees, officers or directors of the Company and members of their immediate families may own stock in publicly traded companies that may compete with
the Company. No member of the immediate family of any officer or director of the Company is directly or indirectly interested in any material contract with the Company. 
  

 4 

 2.13 No Undisclosed Liabilities. Except as set forth in the Financial Statements,
the Company does not have any liabilities (whether accrued, absolute, unliquidated, contingent or otherwise, whether or not known to the Company, whether due or to become due and regardless of when asserted) arising out of transactions entered into
at or prior to the Closing, or any action or inaction at or prior to the Closing or any state of facts existing at or prior to the Closing other than (i) liabilities and obligations that have arisen after June 30, 2009 in the ordinary
course of business (none of which is material and none of which is a liability resulting from breach of contract, breach of warranty, tort, infringement, claim or lawsuit), or (ii) obligations under contracts and commitments incurred in the
ordinary course of business that would not be required to be reflected in financial statements prepared in accordance with generally accepted accounting principles. The Company is not a guarantor or indemnitor of any indebtedness of any other
person, firm or corporation. 
 2.14 Permits. The Company has all franchises, permits, licenses and any similar
authority necessary for the conduct of its business as now being conducted by it, except to the extent the lack of which would not reasonably be expected to have a Material Adversely Effect. The Company is not in default under any of such
franchises, permits, licenses or other similar authority which would be reasonably expected to have a Material Adverse Effect. 
 2.15 Environmental and Safety Laws. 
 (a) Except as set forth in Section 2.16(b), to its knowledge, the
Company is not in violation of any applicable statute, law or regulation relating to the environment or occupational health and safety, and, to its knowledge, no material expenditures are or will be required in order to comply with any such existing
statute, law or regulation. 
 (b) The US Environmental Protection Agency (the “EPA”) has issued recent
guidance regarding the classification of carbon nanotubes under the Toxic Substances Control Act. The EPA has stated that it now considers carbon nanotubes to be “new chemicals” rather than materials previously listed on the TSCA
Inventory, such as synthetic graphite or other carbon compounds. The Company is in the process of reviewing its compliance with this guidance and has filed paperwork with the EPA. Accordingly, the Company withholds any representation or warranty
regarding the matters disclosed in this Section 2.16(b), including its compliance with the new EPA guidance. 
 2.16
Disclosure. The Company has fully provided Investor with all the information that Investor has requested in writing for deciding whether to purchase the Shares. Neither this Agreement (including all the exhibits and schedules hereto) nor any
other statements or certificates made or delivered in connection herewith contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements herein or therein not misleading in light of the
circumstances under which they were made. 
 2.17 Registration Rights. Except as provided in the Investors’ Rights
Agreement, the Company has not granted or agreed to grant any registration rights, including piggyback rights, to any person or entity. 
 2.18 Title to Property and Assets. The property and assets used by the Company in its business are owned by the Company free and clear of all mortgages, liens, loans and encumbrances, except for
(i) statutory liens for the payment of current taxes that are not yet delinquent and (ii) for liens, encumbrances and security interests that arise in the ordinary course of business and/or pursuant to

  

 5 

 
applicable law, and minor defects in title, none of which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. With respect to the property and
assets it leases, the Company is in compliance with such leases and, to its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances, subject to clauses (i)-(ii) of the foregoing sentence, except to the extent the
failure to be in compliance or hold a valid leasehold interest would not reasonably be expected to have a Material Adverse Effect. 
 2.19 Labor Agreements and Actions. The Company is not bound by or subject to any contract, commitment or arrangement with any labor union, and no labor union has requested or, to the Company’s knowledge, has sought to represent
any of the employees, representatives or agents of the Company. There is no strike or other labor dispute involving the Company pending, or to the Company’s knowledge, threatened in writing, that would reasonably be expected to have a Material
Adverse Effect, nor is the Company aware of any labor organization activity involving its employees. The Company is not aware that any officer or key employee, or that any group of key employees, intends to terminate their employment with the
Company, nor does the Company have a present intention to terminate the employment of any of the foregoing. The employment of each officer and employee of the Company is terminable at the will of the Company. The Company is not a party to or bound
by any currently effective employment contract, deferred compensation agreement, bonus plan, incentive plan, profit sharing plan, retirement agreement or other employee compensation agreement, except that pursuant to his employment arrangement, the
Chief Executive Officer of the Company is entitled to certain severance payments and acceleration of options if he is terminated or constructively terminated without cause. To its knowledge, the Company has complied in all material respects with all
applicable state and federal equal employment opportunity and other laws related to employment. 
 2.20 Brokers Fees.
The Company expects to pay third-party finders or advisors finder’s fees (in cash and/or equity) for Shares placed by such third party. For the sake of clarity, no finder’s fees will be paid for Shares not placed by a third-party finder or
advisor. 
 2.21 Intellectual Property. To its knowledge, the Company has rights to all patents, patent applications,
trademarks, service marks, trade names, copyrights, trade secrets, licenses, inventions, information and proprietary rights and processes (collectively, “Intellectual Property”) it needs to operate its business as currently
conducted, other than Intellectual Property that it reasonable believes is invalid or it can obtain rights to through a license or cross-licensing arrangement. 
 2.22 Tax Returns and Payments. There are no federal, state, county, local or foreign taxes dues and payable by the Company which have not been timely paid. There are no accrued and unpaid federal,
state, country, local or foreign taxes of the Company which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by any applicable federal, state, local or foreign governmental agency.
The Company has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and there are in effect no waivers of applicable statutes of limitations with respect to taxes for any year.

 2.23 Insurance. The Company has in full force and effect fire and casualty insurance policies with extended coverage,
sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed. 
 2.24 ERISA. The Company has made all required contributions and has no liability to any such employee benefit plan, other than liability for health plan continuation coverage described in Part 6 of
Title I(B) of Employee Retirement Income Security Act of 1974, as amended, and has complied in all material respects with all applicable laws for any such employee benefit plan. 
  

 6 

 3. Representations and Warranties of Investor. Each Investor hereby, severally and
not jointly, represents, warrants and covenants to the Company that: 
 3.1 Authorization. Such Investor has full power
and authority to enter into this Agreement and the Related Agreements to which it is a party, and each such agreement constitutes its valid and legally binding obligation, enforceable in accordance with its terms except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies, and (iii) to the extent the indemnification provisions contained in the Related Agreements may be limited by applicable federal or state securities laws. 
 3.2 Purchase Entirely for Own Account. This Agreement is made with such Investor in reliance upon such Investor’s
representation to the Company, which by such Investor’s execution of this Agreement, such Investor hereby confirms that the Shares will be acquired for investment for Investor’s own account, not as a nominee or agent, and not with a view
to the resale or distribution of any part thereof, and that such Investor has no present intention of selling, granting any participation in or otherwise distributing the same. By executing this Agreement, such Investor further represents that such
Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Shares. 
 3.3 Disclosure of Information. Such Investor believes it has received all the information it considers necessary or appropriate for
deciding whether to purchase the Shares. Such Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Shares and the business,
properties, prospects and financial condition of the Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of such Investor to rely thereon.

 3.4 Investment Experience. Such Investor is an investor in securities of companies in the development stage and
acknowledges that he/she/it is able to bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares. If other
than an individual, such Investor also represents it has not been organized for the purpose of acquiring the Shares. 
 3.5
Accredited Investor. Such Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D and has reviewed Schedule 3.5 before making this representation to the Company. All of the information in the Investor
Questionnaire delivered by such Investor to the Company in connection with such Investor’s purchase of the Shares remains complete, true and correct as of the Closing. 
 3.6 Restricted Securities. Such Investor understands that the Shares it is purchasing are characterized as “restricted
securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering, and that under such laws and applicable regulations, such Shares may be resold without
registration under the Act only in certain limited circumstances. In the absence of an effective registration statement covering the Shares or an available exemption from registration under the Act, the Shares (and any Common Stock issued on
conversion of the Shares) must be held indefinitely. 
 3.7 No Brokers. Such Investor has not taken any action which
would give rise to any claim by any person for brokerage commissions, finder’s fees or similar payments relating to this Agreement or the transactions contemplated hereby. 
  

 7 

 3.8 Legends. It is understood that the certificates evidencing the Shares and the
Warrants may bear one or all of the following legends: 
 (a) “These securities have not been registered under the
Securities Act of 1933, as amended. They may not be sold, offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or an opinion of counsel satisfactory to the
Company that such registration is not required or unless sold pursuant to Rule 144 of such Act.” 
 (b) Legends required
to indicate that the Shares and the shares of common stock underlying the Warrants are subject to the terms of the Investors Rights Agreement and ROFR Agreement. 
 (c) Any other legend required by applicable laws. 
 4. Conditions to
Investor’s Obligations at Closing. The following conditions must be satisfied by the Company, unless waived by each Investor, in such Investor’s sole and absolute discretion. 
 4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and
correct in all material respects (except that the representations and warranties that are qualified by materiality or Material Adverse Effect shall be true and correct in all respects) on and as of the Closing with the same effect as though such
representations and warranties had been made on and as of the date of the Closing. 
 4.2 Performance. The Company shall
have performed and complied in all material respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 
 4.3 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United
States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be duly obtained and effective, other than such authorizations, approvals or permits or other filings which may
be timely made after such issuance and sale of the Shares. 
 4.4 Restated Certificate. The Restated Certificate shall
have been duly adopted by the Company by all necessary corporate action of its Board of Directors and stockholders, and shall have been filed with and accepted by the Delaware Secretary of State. 
 4.5 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing
and all documents incident thereto shall be reasonably satisfactory in form and substance to Investor, and Investor shall have received all such counterpart original and certified or other copies of such documents as may be reasonably requested.

 4.6 Investors’ Rights Agreement. The Company and certain of the Company’s existing stockholders shall have
executed and delivered the Second Amended and Restated Investors’ Rights Agreement in the form attached hereto as Exhibit A (the “Investors’ Rights Agreement”). 
 4.7 ROFR Agreement. The Company and certain of the Company’s existing stockholders shall have executed and delivered the Second
Amended and Restated Right of First Refusal and Co-Sale Agreement in the form attached hereto as Exhibit B (the “ROFR Agreement”). 
  

 8 

 4.8 Voting Agreement. The Company and certain of the Company’s existing
stockholders shall have executed and delivered the Second Amended and Restated Voting Agreement in the form attached hereto as Exhibit C (the “Voting Agreement”). 
 4.9 General. The holders of Common Stock and/or Preferred Stock shall have amended any other agreement or arrangement, or given any
further consent required to allow the Company to execute and perform this Agreement and the Related Agreements. 
 5.
Conditions to the Company’s Obligations at Closing. The following conditions must be satisfied by each Investor, unless waived in writing by the Company, in the Company’s sole and absolute discretion. 
 5.1 Representations and Warranties. The representations and warranties of such Investor contained in Section 3 shall be true
and correct in all material respects (except that the representations and warranties that are qualified by materiality or Material Adverse Effect shall be true and correct in all respects) on and as of the Closing with the same effect as though such
representations and warranties had been made on and as of the date of the Closing. 
 5.2 Payment of the Purchase Price.
Each Investor shall have delivered to the Company the purchase price for the Shares. 
 5.3 Restated Certificate. The
Restated Certificate shall have been duly adopted by the Company by all necessary corporate action of its Board of Directors and stockholders, and shall have been filed with and accepted by the Delaware Secretary of State. 
 5.4 Securities Exemptions. The offer and sale of the Shares to Investor pursuant to this Agreement shall be exempt from the
registration requirements of the Act, the qualification requirements of the California General Corporation Law and the registration and/or qualification requirements of all other applicable state securities laws. 
 5.5 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing
and all documents incident thereto shall be reasonably satisfactory in form and substance to the Company, and the Company shall have received all such counterpart original and certified or other copies of such documents as may be reasonably
requested. 
 5.6 Investors’ Rights Agreement. Each Investor shall have executed and delivered a counterpart
signature page to the Investors’ Rights Agreement in the form attached hereto as Exhibit A. 
 5.7 ROFR Agreement.
Each Investor shall have executed and delivered a counterpart signature page to the ROFR Agreement in the form attached hereto as Exhibit B. 
 5.8 Voting Agreement. Each Investor shall have executed and delivered a counterpart signature page to the Voting Agreement in the form attached hereto as Exhibit C. 
 5.9 General. Each Investor shall have amended any other agreement or arrangement, or given any further consent required to allow the
Company to execute and perform this Agreement and the Related Agreements. 
 6. Miscellaneous. 
 6.1 Survival. The warranties, representations and covenants of the Company and the Investors contained in or made pursuant to this
Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the Investors or the Company. 
  

 9 

 6.2 Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of, and be binding upon, the respective successors and assigns of the parties (including transferees of any Shares). Nothing in this Agreement, express or implied, is intended to confer upon
any party, other than the parties hereto or their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 6.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to
agreements among California residents entered into and to be performed entirely within California, except with respect to conflict of laws. 
 6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon
personal delivery to the party to be notified, (ii) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (iii) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent to the address as set forth on the signature page hereof or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto. 
 6.6 Responsibility for Brokers Fees. Each Investor indemnifies and holds harmless the Company from any liability for any commission
or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which such Investor or any of its officers, partners, employees or representatives is responsible. The
Company indemnifies and holds harmless each Investor from any liability for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the
Company or any of its officers, employees or representatives is responsible. 
 6.7 Aggregation of Stock. All issued and
outstanding shares of the Series D Preferred Stock and Common Stock issued upon conversion thereof held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under
this Agreement. 
 6.8 Amendments and Waivers. Any term of this Agreement may be amended, and the observance of any term
of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of Shares and/or Common Stock issued upon conversion thereof
representing at least a majority of the aggregate number of shares of Common Stock into which the Shares then are convertible and/or have been converted (excluding any of such shares that have been sold to the public or pursuant to SEC Rule 144).

 6.9 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such
provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 
  

 10 

 6.10 Entire Agreement. This Agreement and the documents referred to herein
constitute the entire agreement among the parties, and this Agreement supersedes all prior and contemporaneous written and oral agreements, relating to the subject matter hereof. 
 6.11 Counterparts; Facsimile/PDF Signatures. This Agreement may be executed in two or more counterparts, and by facsimile signatures
or portable document format (.pdf or similar format), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [SIGNATURE PAGE FOLLOWS] 
  

 11 

 [Company Signature Page to Subscription Agreement] 
  

							
	Dated: SEPTEMBER 30, 2009	 		  	COMPANY:
			
		 		  	UNIDYM, INC.
		 		  	a Delaware corporation
				
		 		  	By:	 	  

				
		 		  	Address:	 	    1244 Reamwood Drive
		 		  		 	    Sunnyvale, CA

 [Investor Signature Page to Subscription Agreement] 
 I HEREBY REPRESENT THAT I HAVE READ AND UNDERSTOOD THE SUBSCRIPTION AGREEMENT. 
 Dated: 
 Subscription: I hereby subscribe for the following number of Shares at the
Purchase Price indicated: 
 Total Number of Shares:              shares

 Total Purchase Price ($0.30 Per Share): $         
  

			
	  

			
	 Please print the exact name(s) in which the Shares will be issued
	  	

  

			
		
	Print Name of Signer:	 	  

  

			
		
	 Signature:
	 	  

  

			
		
	 Title of Signer (if purchaser is an entity):
	 	  

  

			
		
	Social Security # or Tax Id#:	 	  

  

			
		
	Address:	 	  

	  
  

  

			
		
	City, State & Zip:	 	  

  

			
		
	Phone:	 	  

  

			
		
	Facsimile:	 	  

  

			
		
	Email:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]